Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
Evaluate Omnium
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
intrinsic
December 13, 2017
Barricaid panel rejection means a long wait for Intrinsic
November 16, 2017
Pressure off Corvia after positive phase II
November 07, 2017
Event – Barricaid implant could cut costs – if it works
May 13, 2013
Elan’s long-odds Theravance bet centres on bifunctional phase II project
March 09, 2012
Shire tacks away from industry norms with head-to-head study
September 10, 2010
Therapeutic focus - Melanoma awaiting breakthrough but data approaching
December 10, 2008
Merck puts hope in copying
September 04, 2008
Alexza making solid progress
November 19, 2007
Proof of value – the new proof of concept?
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 29, 2020
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
April 16, 2020
Evaluate Vantage COVID-19 Report
Editor's Picks
September 11, 2020
Esmo 2020 preview – late-breaking immunotherapy
September 11, 2020
Esmo 2020 preview – a kidney cancer showdown gets star billing
September 07, 2020
Big pharma spinouts grow up
September 09, 2020
Covid vaccine developers face nervous wait
September 03, 2020
Medtechs that book the most sales per employee face the greatest losses
